Sviss - franska - Swissmedic (Swiss Agency for Therapeutic Products)

rubimed ag - washington, d21, 14.285714 %; gold metallic, d21, 14.285714 %; cetraria islandica, d21, 14.285714 %; drüsen thymi, d21, 14.285714 %; eisen-metallic, c50, 14.285714 %; zink valerianicum, c200, 14.285714 %; eucalyptus globulus, d21, 14.285714 % - tropfen / spray, globuli - d - washington, d21, 14.285714 %; or métallique, d21, 14.285714 %; cetraria islandica, d21, 14.285714 %; glandes de thymidine, d21, 14.285714 %; fer métallique, c50, 14.285714 %; zinc valerianicum, c200, 14.285714 %; eucalyptus globulus, d21, 14.285714 % - homöopathisch

Sviss - franska - Swissmedic (Swiss Agency for Therapeutic Products)

weleda ag - washington, d3, de 200,0 mg / 1 gramm onopordum acanthium, 100%, 5,0 mg / 1 gramm primula printemps, 100%, 5,0 mg / 1 gramm cœur, d6, de 200,0 mg / 1 gramm selenicereus grandiflorus, d4, de 200,0 mg / 1 gramm or métallisé, d15, de 200,0 mg / 1 gramm hyoscyamus niger, 100%, 0,02 mg / 1 gramm - gouttes / spray - b - washington, d3, de 200,0 mg / 1 gramm; la onopordum acanthium, 100%, 5,0 mg / 1 gramm; primula printemps, 100%, 5,0 mg / 1 gramm; le coeur, d6, de 200,0 mg / 1 gramm; selenicereus grandiflorus, d4, de 200,0 mg / 1 gramm; or métallique, d15, de 200,0 mg / 1 gramm; hyoscyamus niger, 100%, 0,02 mg / 1 gramm

Sviss - franska - Swissmedic (Swiss Agency for Therapeutic Products)

spagyros ag - washington, tm, 26.5 %; solidago virgaurea, tm, 7.5 %; valeriana officinalis d1, 3.5 %; valeriana officinalis, tm, 3.5 %; sanguisorba officinalis, tm, 7.5 %; solidago virgaurea d1, 7.5 %; sanguisorba officinalis, d1, 7.5 %; löwenzahn officinale, tm, 5.0 %; washington, d1, 26.5 %; löwenzahn officinale, d1, 5.0 % - tropfen / spray - d - washington, tm, de 26,5 %; solidago virgaurea, tm, de 7,5 %; valeriana officinalis, tm, de 3,5 %; valeriana officinalis, d1, de 3,5 %; sanguisorba officinalis tm, de 7,5 %; solidago virgaurea, d1, de 7,5 %; sanguisorba officinalis, d1, de 7,5 %; pissenlit officinale, tm, de 5,0 %; washington, d1, de 26,5 %; pissenlit officinale, d1, 5.0 % - homöopathisch-spagyrisch

Sviss - franska - Swissmedic (Swiss Agency for Therapeutic Products)

wala schweiz gmbh - washington, 30%, 20.0 %; hypericum durchbohrt, d2, 0.5 %; valeriana officinalis, 20%, 15.0 %; salix viminalis, d2, 0.167 %; hafer sativa, 20%, 40.0 %; passiflora blau, 20%, 5.0 %; salix purpurea, d2, 0.167 %; salix alba, d2, 0.167 %; humulus lupulus, 20%, 15.0 % - sonstige oral - d - washington, 30% 20,0% par; hypericum percé, d2, de 0,5 %; valeriana officinalis, 20%, de 15,0 %; salix viminalis, d2, 0.167 %; salix purpurea, d2, 0.167 %; passiflore bleue, 20% à 5,0 %; sativa l'avoine, 20%, de 40,0 %; salix alba, d2, 0.167 %; humulus lupulus, 20%, 15,0% en - anthroposophisch

Sviss - franska - Swissmedic (Swiss Agency for Therapeutic Products)

weleda ag - washington éthanol. la digestion tm, onopordon de fleurs fraîches, primulae de fleurs fraîches, hyoscyamus niger à partir de l'usine tm - dilutio - washington éthanol. la digestion tm 500 mg, la digestion ethanolica 50 mg de onopordon de fleurs fraîches 12,5 mg, ratio: 1:3.1, la digestion ethanolica 50 mg de primulae de fleurs fraîches de 12,5 mg et de hyoscyamus niger à partir de l'usine tm 1 mg, ratio: 1:3.1, la solution pro 1 g, corresp. ethanolum 38 % v/v. - sans indication, - anthroposophika

Belgía - franska - Ecolab

ecolab deutschland gmbh -

Belgía - franska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

galderma benelux b.v. - peroxyde de benzoyle hydre 50 mg/ml - suspension pour application cutanée - 5 % - peroxyde de benzoyle 50 mg/ml - benzoyl peroxide

Sviss - franska - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus souche a/guangdong-maonan/swl1536/2019 (h1n1)-pdm09: reassortant virus cnic-19 derived from a/guangdong-maonan/swl1536/2019), haemagglutininum influenzae a (h3n2) (virus souche a/hong kong/2671/2019 (h3n2)-like: reassortant virus ivr-208 derived from a/hong kong/2671/2019), haemagglutininum influenzae b (virus souche b/washington/02/2019 (victoria lineage)) - suspension pour injection dans une seringue pré-remplie - haemagglutininum influenzae a (h1n1) (virus souche a/guangdong-maonan/swl1536/2019 (h1n1)-pdm09: reassortant virus cnic-19 derived from a/guangdong-maonan/swl1536/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/hong kong/2671/2019 (h3n2)-like: reassortant virus ivr-208 derived from a/hong kong/2671/2019) 15 µg, haemagglutininum influenzae b (virus souche b/washington/02/2019 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013 (yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.72 mg, kalium 0.08 mg, residui: formaldehydum, octoxinolum-9, neomycinum, ovalbuminum. - immunisation active contre l'influenza, dès le 6ème mois - les vaccins

Sviss - franska - Swissmedic (Swiss Agency for Therapeutic Products)

mylan pharma gmbh - haemagglutininum influenzae a (h1n1) (virus-stamm a/guangdong-maonan/swl1536/2019 (h1n1)-pdm09: reassortant virus cnic-1909 derived from a/guangdong-maonan/swl1536/2019), haemagglutininum influenzae a (h3n2) (virus-stamm a/hong kong/2671/2019 (h3n2)-like: reassortant virus ivr-208 derived from a/hong kong/2671/2019), haemagglutininum influenzae b (virus-stamm b/washington/02/2019 (victoria lineage)) - suspension injectable - haemagglutininum influenzae a (h1n1) (virus-stamm a/guangdong-maonan/swl1536/2019 (h1n1)-pdm09: reassortant virus cnic-1909 derived from a/guangdong-maonan/swl1536/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus-stamm a/hong kong/2671/2019 (h3n2)-like: reassortant virus ivr-208 derived from a/hong kong/2671/2019) 15 µg, haemagglutininum influenzae b (virus-stamm b/washington/02/2019 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus-stamm b/phuket/3073/2013 (yamagata lineage)) 15 µg, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, natrii chloridum, calcii chloridum dihydricum, magnesii chloridum hexahydricum, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 2.0 mg, kalium 0.1 mg, residui: cetrimidum, formaldehydum, gentamicini sulfas, polysorbatum 80, ovalbuminum. - aktive immunisierung gegen influenza, ab 3 jahren - les vaccins

Sviss - franska - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/2570/2019 (h1n1)-pdm09: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus souche a/cambodia/e0826360/2020 (h3n2)-like: reassortant virus ivr-221 derived from a/cambodia/e0826360/2020), haemagglutininum influenzae b (virus souche b/washington/02/2019 (victoria lineage)) - suspension pour injection dans une seringue pré-remplie - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/2570/2019 (h1n1)-pdm09: reassortant virus ivr-215 derived from a/victoria/2570/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/cambodia/e0826360/2020 (h3n2)-like: reassortant virus ivr-221 derived from a/cambodia/e0826360/2020) 15 µg, haemagglutininum influenzae b (virus souche b/washington/02/2019 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013 (yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.72 mg, kalium 0.08 mg, residui: formaldehydum, octoxinolum-9, neomycinum, ovalbuminum. - immunisation active contre l'influenza, dès le 6ème mois - les vaccins